Tocilizumab in patients with severe COVID-19: A single-center observational analysis
중증 코로나19 환자의 토실리주맙: 단일 센터 관찰 분석
Observational Study
[키워드] Admission
Analysis
baseline
benefit
changes in
clinical
Clinical improvement
common
Comorbidity
coronavirus disease
COVID-19
CRP
cytokine
cytokine release
Cytokine release syndrome
Cytokine storm
decrease
develop
Diabetes Mellitus
diagnosed with COVID-19
died
discharged
disease severity
dose
elevated
evaluate
evaluated
expired
glucocorticoid
hospital
Hydroxychloroquine
hypertension
IL-6
IL-6 antagonist
interleukin-6 receptor
marker
Mortality
Most patient
oxygen-support
oxygenation status
Patient
patient population
proinflammatory
Protein
reported
retrospective
severe COVID-19
Severe respiratory distress
single-center
Support
thought
Tocilizumab
transferred
Treatment
Trial
Ventilation
worsened
[DOI] 10.1002/jmv.26191 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1002/jmv.26191 PMC 바로가기 [Article Type] Observational Study